Exploration of Medicine

Drug	Type	Total	Patients (%)
Amphetamines	Stimulant	30	51
Alcohol	Depressant	26	44
Cannabis	Depressant	22	37
Pregabalin	Depressant	21	36
Benzodiazepines	Depressant	16	27
Opiates/Opioids	Depressant	12	20
Tramadol	Depressant	8	14
Synthetic cannabinoids	Stimulant/Depressant/Hallucinogen	1	2

Declarations

Acknowledgments

The authors acknowledge the support provided by the National Rehabilitation Centre, Abu Dhabi, UAE for the medical and laboratory resources involved in the patient analysis as well as staffing resources for the collation of data and scientific writing of this article. The authors also acknowledge the support provided by Medical University of Lodz for staffing resources related to the conception and scientific writing of this article.

Author contributions

AEAA: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing—original draft. WE: Conceptualization, Methodology, Visualization, Writing—original draft. AA, SAM, MAR, and MA: Formal Analysis, Investigation, Methodology, Resources. SE: Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Ethical permissions in relation to the National Rehabilitation Center Ethics Committee were followed for patient involvement.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Ojo O, Wang XH, Ojo OO, Ibe J. The effects of substance abuse on blood glucose parameters in patients with diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health. 2018;15:2691. [DOI] [PubMed] [PMC]

Warner EA, Greene GS, Buchsbaum MS, Cooper DS, Robinson BE. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med. 1998;158:1799–802. [DOI] [PubMed]

Global report on diabetes [Internet]. Geneva: World Health Organization; [cited 2023 Feb 22]. Available from: https://www.who.int/publications/i/item/9789241565257

Sheldon BH, Quin JD. Diabetes and illicit drug use. Pract Diabetes. 2005;22:222–4. [DOI]

Diabetes Australia. Drug use and type 1 diabetes. 2016.

Ng RS, Darko DA, Hillson RM. Street drug use among young patients with type 1 diabetes mellitus in the UK. Diabetic Med. 2004;21:295–6. [DOI] [PubMed]

Johnson KH, Bazargan M, Charpital CJ. Alcohol, tobacco and drug use and the onset of type 2 diabetes mellitus among inner-city minority patients. J Am Board Fam Pract. 2001;14:430–6. [PubMed]

Hicks D. Recreational drugs and their impact on diabetes. J Diabetes Nurs. 2016;20:110–4.

Lewis D, van den Heuvel C, Kenneally M, Byard RW. Methamphetamine use and the risk of diabetic ketoacidosis. Med Sci Law. 2022;62:39–42. [DOI] [PubMed]

10.

Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D’Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for a hyperglycaemic effect of morphine. Diabetologia. 1982;22:379. [DOI] [PubMed]

11.

Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984;7:92–8. [DOI] [PubMed]

12.

Yazici ZMC, Bilge B, Bolkent S. Anti-inflammatory potential of delta-9-tetrahydrocannabinol in hyperinsulinemia: an experimental study. Mol Biol Rep. 2022;49:11891–9. [DOI] [PubMed]

13.

Al Ghaferi HA, Ali AY, Gawad TA, Wanigaratne S. Developing substance misuse services in United Arab Emirates: the National Rehabilitation Centre experience. BJPsych Int. 2017;14:92–6. [DOI] [PubMed] [PMC]

14.

Al Ghafri H, Abuelgasim EA, Ali AY, Al Mamari S, Gawad TA, Alawadhi A, et al. A 6-year review of drug trends in the United Arab Emirates from the perspective of the National Rehabilitation Center (NRC) Abu Dhabi. Curr Top Toxicol. 2020;16:151–6.

15.

Roque-Bravo R, Silva RS, Malheiro RF, Carmo H, Carvalho F, da Silva DD, et al. Synthetic cannabinoids: a pharmacological and toxicological overview. Annu Rev Pharmacol Toxicol. 2022;63:187–209. [DOI] [PubMed]